As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for ...

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Shaperon secures phase 2 trials for atopic dermatitis treatment Nugel after positive review Shaperon obtains approval for ...

Atopic dermatitis, or eczema ... your doctor or dermatologist may recommend treatments such as: medications to reduce allergies and itching, such as antihistamines topical creams with a steroid ...

Spain's Almirall has announced strategic plans at the 43rd JP Morgan Healthcare Conference based on expected double-digit ...

Sanofi aims to boost competition in the atopic dermatitis market, following Dupixent's success, with new treatments like ...

Shaperon successfully completed part 1 of the multinational phase 2 clinical trial of 'HY209 gel' targeting patients with ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD ... (YJT), which holds rights to the drug. Called NM26, the bispecific targets IL-4 receptors ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...